GRAIL, Inc. (GRAL)

63.04 +0.29 (+0.46%) USD  |  NASDAQ  |  May 07, 16:00
64.00 +0.96 (+1.52%) After-Hours: 07:27
More

GRAIL SG&A Expense (TTM) : 195.74M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for GRAL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Biodesix, Inc. 67.10M
FONAR Corp. 30.72M
Interpace Biosciences, Inc. 19.40M
Thermo Fisher Scientific, Inc. 8.46B
XWELL, Inc. 16.00M